Douglas M. Hunt - Feb 12, 2024 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Role
The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.
Signature
/s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt
Stock symbol
PBYI
Transactions as of
Feb 12, 2024
Transactions value $
$0
Form type
4
Date filed
2/14/2024, 05:54 PM
Previous filing
Jan 5, 2024
Next filing
Jul 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBYI Common Stock Award $0 +37.9K +36.68% $0.00 141K Feb 12, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBYI Stock Option (Right to Buy) Award $0 +52.5K $0.00 52.5K Feb 12, 2024 Common Stock 52.5K $6.36 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to the Grantee's continued service with the Company through the applicable vesting date.
F2 Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to the Optionee's continued service with the Company through the applicable vesting date.

Remarks:

The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.